A5101520927- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Pharmacology and Obesity Treatment
- Pancreatic function and diabetes
- Plant-based Medicinal Research
- Diet and metabolism studies
- Pharmaceutical studies and practices
- Receptor Mechanisms and Signaling
- Toxin Mechanisms and Immunotoxins
- Pain Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Real-time simulation and control systems
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Pharmacological Effects of Natural Compounds
- Blood Pressure and Hypertension Studies
- Heart Rate Variability and Autonomic Control
Jinan Central Hospital
2015-2025
Shandong First Medical University
2023-2025
National Health and Family Planning Commission
2024
National Clinical Research
2024
Shanghai Jiao Tong University
2024
Shandong University
2015-2024
BackgroundEffective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear.MethodsWe enrolled 50 years of age or older diabetes, elevated blood pressure, and an increased risk cardiovascular disease at 145 clinical sites across China. Patients were randomly assigned to receive intensive treatment that targeted a pressure less than 120 mm Hg standard 140 up 5 years. The primary outcome was composite nonfatal stroke, myocardial infarction, hospitalization...
Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy safety of 24-week treatment mazdutide up to 6 mg in Chinese overweight adults or with obesity, as an interim analysis randomised, two-part (low doses high dose 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight (body-mass index [BMI] ≥24 kg/m
Abstract The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) evaluate the safety efficacy IBI362 (LY3305677), GLP-1 glucagon dual agonist, in Chinese patients with T2D. A total 43 T2D were enrolled three cohorts nine centres China randomised each...
ABSTRACT Background Dulaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has been approved for improving glycemic control and reducing the risk of cardiovascular (CV) adverse events. A previous result in healthy Chinese male subjects demonstrated pharmacokinetic (PK) similarity LY05008 licensed product dulaglutide, with comparable safety immunogenicity profiles. well‐controlled phase 3 study an adequate sample size was subsequently conducted efficacy evaluation. Methods In...
Abstract Aim Fotagliptin is a novel dipeptidyl peptidase‐4 inhibitor for glycaemic control in patients with type 2 diabetes (T2D). This trial aimed to assess the efficacy and safety of fotagliptin add‐on metformin T2D. Materials Methods In this phase 3 randomised, double‐blind, placebo‐controlled study, T2D who had inadequate using alone were randomly allocated or placebo at 2:1 ratio 24‐week double‐blind treatment period, followed by an open‐label all patients, making up total 52 weeks. All...
Many patients with diabetic peripheral neuropathic pain (DPNP) experience inadequate relief, despite best available medical treatments. There are no approved and effective therapies for DPNP in China.
In this paper, we aimed to look for a potent long acting GLP-1 receptor agonist diabetes treatment. work, constructed the eukaryotic expression vector of GLP-1-Exendin-4/IgG4 (Fc)-pOptiVEC™-TOPO<sup>®</sup> and then transfected it into Chinese hamster ovary DG44 (CHO/DG44) cells using liposome method. Then beta-cell line INS-1 were treated with purified (Fc) fusion protein (0.01, 0.1, 1.0 mM respectively) randomly assigned 2 groups, each group grown in KRB buffer presence 2.8 or 16.8 glucose...
To evaluate the efficacy and safety of janagliflozin in Chinese patients with type 2 diabetes (T2D) inadequately controlled metformin monotherapy.This multicentre phase 3 trial included a 24-week, randomized, double-blind, placebo-controlled period, followed by 28-week extension period. Patients (N = 421) HbA1c 7.0% or higher 10.5% less were randomized (1:1:1) to receive once-daily placebo, 25 50 mg. After 24-week treatment on placebo re-randomized (1:1) mg for additional treatment, whereas...
Abstract Aims/hypothesis Glucagon-like peptide 1 receptor agonists (GLP-1 RA) such as exenatide are used monotherapy and add-on therapy for maintaining glycaemic control in patients with type 2 diabetes mellitus. The current study investigated the safety efficacy of once-weekly PB-119, a PEGylated injection, treatment-naive diabetes. Methods In this Phase II, randomised, placebo-controlled, double-blind study, we randomly assigned Chinese 1:1:1:1 ratio to receive subcutaneous placebo or one...
To evaluate the efficacy and safety of janagliflozin, a selective renal sodium-glucose cotransporter-2 inhibitor, as monotherapy in drug-naive Chinese patients with type 2 diabetes mellitus (T2DM).This Phase 3 trial included 24-week, multicentre, randomized, double-blind, placebo-controlled period, followed by 28-week extension period. A total 432 glycated haemoglobin (HbA1c) levels ≥7.0% (53 mmol/mol) ≤10.5% (91 were randomized (1:1:1) to receive once-daily placebo, 25 mg or 50...
Dipeptidyl peptidase-4 inhibitors (DPP-4i) have become firmly established in treatment algorithms and national guidelines for improving glycemic control type 2 diabetes mellitus (T2DM).To report the findings from a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, which was designed to assess efficacy safety of novel DPP-4 inhibitor fotagliptin treatment-naive patients with T2DM.Patients T2DM were randomized receive (n = 230), alogliptin 113) or placebo 115)...
Objective: To compare the efficacy and safety of Tonghua Dongbao's insulin aspart injection (Rishulin) NovoRapid (Novo Nordisk) in treatment diabetes. Methods: A 26-week, randomized, open-label, parallel-group, positive control drug non-inferiority trial was conducted 23 centers China. total 563 diabetes with poor blood glucose treated for at least 3 months before were included. The subjects randomized(stratified block random method) into those receiving Rishulin or a ratio 3∶1. Both groups...